Crinetics Pharmaceuticals, Inc. — Director's Dealing 2018

Jul 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2018-07-20

Reporting Person: Versant Venture Capital V, L.P. (10% Owner)
Reporting Person: Versant Affiliates Fund V, L.P. (10% Owner)
Reporting Person: Versant Ophthalmic Affiliates I, L.P. (10% Owner)
Reporting Person: Versant Venture Capital V (Canada), LP (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-20	Common Stock	C	2557392	—	Acquired	2557392	Indirect
2018-07-20	Common Stock	C	76927	—	Acquired	76927	Indirect
2018-07-20	Common Stock	C	85253	—	Acquired	85253	Indirect
2018-07-20	Common Stock	C	194629	—	Acquired	194629	Indirect
2018-07-20	Common Stock	C	412534	—	Acquired	2969926	Indirect
2018-07-20	Common Stock	C	12409	—	Acquired	89336	Indirect
2018-07-20	Common Stock	C	13736	—	Acquired	98989	Indirect
2018-07-20	Common Stock	C	31396	—	Acquired	226025	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-20	Series A Preferred Stock	$	C	8413817	Disposed		Common Stock (2557392)	Indirect
2018-07-20	Series A Preferred Stock	$	C	253091	Disposed		Common Stock (76927)	Indirect
2018-07-20	Series A Preferred Stock	$	C	280485	Disposed		Common Stock (85253)	Indirect
2018-07-20	Series A Preferred Stock	$	C	640332	Disposed		Common Stock (194629)	Indirect
2018-07-20	Series B Preferred Stock	$	C	1357240	Disposed		Common Stock (412534)	Indirect
2018-07-20	Series B Preferred Stock	$	C	40826	Disposed		Common Stock (12409)	Indirect
2018-07-20	Series B Preferred Stock	$	C	45192	Disposed		Common Stock (13736)	Indirect
2018-07-20	Series B Preferred Stock	$	C	103293	Disposed		Common Stock (31396)	Indirect

Footnotes

F1: The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date.

F2: These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein.

F3: These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VAF V; however, they each disclaim beneficial ownership of the shares held by VAF V, except to the extent of their pecuniary interests therein.

F4: These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VOA; however, they each disclaim beneficial ownership of the shares held by VOA, except to the extent of their pecuniary interests therein.

F5: These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), LP ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein.

F6: This report on Form 4 is jointly filed by VVC V, VAF V, VOA and VVC CAN. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.